Leonid Timashev

Q: How accurate are Leonid Timashev's stock ratings?

About 50% of Leonid's ratings were profitable over a one-year hold, with an average return of +1.0% per rating, measured by 13Foresight from historical prices.

Q: How is Leonid ranked?

Leonid Timashev is ranked #2176 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

RBC Capital

Wall Street Analyst

★★★☆☆

#2176

on 13Foresight · ranked by our own returns

49%

Success Rate

+0.5%

Average Return

69 of 140 calls profitable · -142.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 49% of Leonid Timashev's ratings turned a profit when each position was held for 1 year — averaging +0.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

254 Buy 37 Hold 0 Sell

Leonid's Stock Coverage 27 ratings · 2026-11-13

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
EXEL Exelixis	Oct 29, 2026	HOLD	Buy -34.0% avg upside 34 analysts	$58.00 16.34% Downside	+4.5%	·
BCYC Bicycle Therapeutics	Oct 29, 2026	HOLD	Strong Buy +557.2% avg upside 21 analysts	$5.00 36.54% Upside	-1.3%	·
INSM Insmed	Oct 29, 2026	BUY	Strong Buy +51.3% avg upside 37 analysts	$195.00 73.13% Upside	+7.5%	·
RVMD Revolution Medicines	Oct 27, 2026	BUY	Strong Buy +8.2% avg upside 36 analysts	$260.00 35.85% Upside	-6.9%	·
IDYA IDEAYA Biosciences	Oct 27, 2026	BUY	Strong Buy +48.3% avg upside 31 analysts	$48.00 50.27% Upside	-8.3%	·
VSTM Verastem	Oct 27, 2026	BUY	Strong Buy +55.8% avg upside 24 analysts	$19.00 94.80% Upside	-16.4%	·
ONC BeOne Medicines	Oct 27, 2026	BUY	Strong Buy -1.2% avg upside 29 analysts	$459.00 23.88% Upside	+13.3%	·
BHVN Biohaven Ltd.	Oct 27, 2026	HOLD	Buy +51.3% avg upside 25 analysts	$22.00 42.61% Upside	-9.7%	·
EWTX Edgewise Therapeutics	Oct 27, 2026	BUY	Strong Buy +18.0% avg upside 16 analysts	$59.00 51.65% Upside	+13.3%	·
XNCR Xencor	Oct 26, 2026	BUY	Strong Buy +31.8% avg upside 29 analysts	$43.00 44.29% Upside	+35.0%	·
CATX Perspective Therapeutics	Oct 26, 2026	HOLD	Strong Buy +759.3% avg upside 24 analysts	$4.00 247.90% Upside	-28.9%	·
AXSM Axsome Therapeutics	Oct 14, 2026	BUY	Strong Buy +63.9% avg upside 30 analysts	$295.00 104.32% Upside	-13.7%	·
CYTK Cytokinetics	Oct 14, 2026	BUY	Strong Buy +43.4% avg upside 36 analysts	$113.00 79.34% Upside	-12.2%	·
NUVB Nuvation Bio	Oct 12, 2026	BUY	Strong Buy +178.0% avg upside 18 analysts	$20.00 320.13% Upside	-16.7%	·
ALKS Alkermes	Oct 08, 2026	BUY	Strong Buy -3.4% avg upside 34 analysts	$56.00 23.60% Upside	+15.5%	·
PYXS Pyxis Oncology	Oct 08, 2026	BUY	Strong Buy +349.6% avg upside 15 analysts	$6.00 231.56% Upside	-23.1%	·
LEGN Legend Biotech	Oct 08, 2026	BUY	Strong Buy +182.3% avg upside 27 analysts	$56.00 158.99% Upside	-0.9%	·
ADCT ADC Therapeutics	Oct 08, 2026	HOLD	Strong Buy +239.2% avg upside 12 analysts	$2.00 30.73% Upside	-14.5%	·
JAZZ Jazz Pharmaceuticals	Oct 08, 2026	BUY	Strong Buy +16.2% avg upside 36 analysts	$296.00 37.03% Upside	+8.6%	·
CRMD Cormedix	Oct 08, 2026	BUY	Strong Buy +165.8% avg upside 13 analysts	$14.00 145.87% Upside	-26.6%	·
NAMS NewAmsterdam Pharma Company	Oct 05, 2026	BUY	Strong Buy +136.0% avg upside 19 analysts	$42.00 109.38% Upside	-11.4%	·
JNJ Johnson & Johnson	Sep 09, 2026	BUY	Strong Buy -9.1% avg upside 40 analysts	$287.00 5.12% Upside	+6.2%	·
PRAX Praxis Precision Medicines	Aug 06, 2026	BUY	Strong Buy +99.2% avg upside 25 analysts	$462.00 61.60% Upside	-14.1%	·
CGON CG Oncology, Inc.	Aug 06, 2026	BUY	Strong Buy +33.1% avg upside 17 analysts	$79.00 22.12% Upside	-4.5%	·
CMPS COMPASS Pathways	Aug 05, 2026	BUY	Strong Buy +91.9% avg upside 20 analysts	$21.00 81.46% Upside	-33.1%	·
DSGN Design Therapeutics	Aug 03, 2026	BUY	Strong Buy +66.1% avg upside 9 analysts	$20.00 87.28% Upside	-20.0%	·
JSPR Jasper Therapeutics	May 14, 2026	HOLD	Buy +5062.9% avg upside 18 analysts	$3.00 476.61% Upside	·	·

🔒 22 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Leonid Timashev — Frequently Asked Questions

How accurate are Leonid Timashev's stock ratings?

Based on the calls 13Foresight could measure, about 50% of Leonid's ratings were profitable over a one-year hold, with an average return of +1.0% per rating, or +14.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Leonid ranked on 13Foresight?

Leonid Timashev is currently ranked #2176 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Leonid cover?

Leonid most recently has ratings on EXEL, BCYC, INSM, RVMD, IDYA, VSTM, ONC, BHVN, EWTX, XNCR, CATX, AXSM and 15 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Leonid Timashev

Rating Distribution

Welcome to 13Foresight!